Professor | Lushan Yu | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Lushan Yu
Contact Information	yuls@zju.edu.cn
Language ability	Chinese, English
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Lushan Yu

Contact Information

yuls@zju.edu.cn

Language ability

Chinese, English

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Pharmaceutical Sciences
Academic Background & Achievements	2005 - PhD in Medicine: Zhejiang University 2005-2007 - Postdoctoral Research: Zhejiang University 2011-2012 - Visiting Scholar: University of Pittsburgh School of Pharmacy Published over 100 academic papers, including 70 SCI-indexed papers Authored over 10 books Led 6 National Natural Science Foundation projects Received Zhejiang Province Science and Technology Award (Second Prize) twice Received Ministry of Education Science and Technology Progress Award (Second Prize)
Work Experience	2007-present - Zhejiang University - Faculty Member 2011-2012 - University of Pittsburgh School of Pharmacy - Visiting Scholar
Awards	Zhejiang Province Science and Technology Award (Second Prize): Twice Ministry of Education Science and Technology Progress Award (Second Prize): Once

University/Lab Affiliation and Title

Zhejiang University

Faculty

Pharmaceutical Sciences

Academic Background & Achievements

2005 - PhD in Medicine: Zhejiang University
2005-2007 - Postdoctoral Research: Zhejiang University
2011-2012 - Visiting Scholar: University of Pittsburgh School of Pharmacy
Published over 100 academic papers, including 70 SCI-indexed papers
Authored over 10 books
Led 6 National Natural Science Foundation projects
Received Zhejiang Province Science and Technology Award (Second Prize) twice
Received Ministry of Education Science and Technology Progress Award (Second Prize)

Work Experience

2007-present - Zhejiang University - Faculty Member
2011-2012 - University of Pittsburgh School of Pharmacy - Visiting Scholar

Awards

Zhejiang Province Science and Technology Award (Second Prize): Twice
Ministry of Education Science and Technology Progress Award (Second Prize): Once

Areas of Focus	Drug Metabolism and Pharmacokinetics Research Drug Analysis and New Drug Quality Standards Research Epigenetic Mechanisms in Drug Metabolism Enzymes and Transporters
Publications	Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin, Liu YQ, Zheng XL, Yu QQ, Wang H, Tan FQ, Zhu QY, Yuan LM, Jiang HD, Yu LS, Zeng S, 2016 Downregulation of the farnesoid X receptor promotes colorectal tumorigenesis by facilitating enterotoxigenic Bacteroides fragilis colonization, Guo SH, Peng Y, Lou Y, Cao LJ, Liu JQ, Lin NM, Cai S, Kang Y, Zeng S, Yu LS, 2022 Oncopeptide MBOP encoded by LINC01234 promotes colorectal cancer through MAPK signaling pathway, Tang CY, Zhou Y, Sun W, Hu HH, Liu YX, Chen L, Ou FT, Zeng S, Lin NM, Yu LS, 2022 Blockade LAT1 mediates methionine metabolism to overcome oxaliplatin resistance under hypoxia in renal cell carcinoma, Xu QW, Liu YX, Sun W, Song TT, Jiang XT, Zeng K, Zeng S, Chen L, Yu LS, 2022 The metabolic stability of antimicrobial peptides IK8 in plasma and liver S9, Mao YY, Zhou SJ, Xu MC, Zeng S, Fan WM, Yu LS, Lin NM, 2021 Metastatic colorectal cancer: Perspectives on long non-coding RNAs and promising therapeutics, Tang CY, Liu JQ, Hu QQ, Zeng S, Yu LS, 2021 Epigenetic regulation of intestinal peptide transporter PEPT1 as a potential strategy for colorectal cancer sensitization, Wang YH, Wang JQ, Yang LR, Qiu LQ, Hua YH, Wu SX, Zeng S, Yu LS, Zheng XL, 2021 Regulation of MRP4 Expression by circHIPK3 via Sponging miR-124-3p/miR-4524-5p in Hepatocellular Carcinoma, Hu HH, Wang Y, Qin ZY, Sun W, Chen YH, Wang JQ, Wang YY, Nie J, Chen L, Cai S, Yu LS, Zeng S, 2021 INTEDE: interactome of drug-metabolizing enzymes, Yin JY, Li FC, Zhou Y, Mou MJ, Lu YJ, Chen KL, Xue J, Luo YC, Fu JB, He X, Gao JQ, Zeng S, Yu LS, Zhu F, 2021 miR-224-5p Contained in Urinary Extracellular Vesicles Regulates PD-L1 Expression by Inhibiting Cyclin D1 in Renal Cell Carcinoma Cells, Qin ZY, Hu HH, Sun W, Chen L, Jin SN, Xu QW, Liu YX, Yu LS, Zeng S, 2021 LncRNA regulation: New frontiers in epigenetic solutions to drug chemoresistance, Zhou Y, Sun W, Qin ZY, Zeng S, Yu LS, 2020 The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma, Chen L, Wang ZY, Xu QW, Liu YX, Chen L, Guo SH, Wang H, Zeng K, Liu JQ, Zeng S, Yu LS, 2020 6-Dithio-2'-deoxyguanosine analogs induce reactive oxygen species-mediated tumor cell apoptosis via bi-targeting thioredoxin 1 and telomerase, Zhang Y, Zhou JB, Ye Q, Zeng K, Pan J, Chen L, Wang YY, Yang B, He QJ, Gao JQ, Zeng S, Yu LS, 2020 Epigenetic mechanisms underlying OSTβ repression in colorectal cancer, Zhou Y, Ye CN, Lou Y, Liu JQ, Ye S, Chen L, Lei JX, Guo SH, Zeng S, Yu LS, 2020 The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents, Zhou JB, Kang Y, Chen L, Wang H, Liu JQ, Zeng S, Yu LS, 2020 Research and development of drug delivery systems based on drug transporter and nano-formulation, Peng Y, Chen L, Ye S, Kang Y, Liu JQ, Zeng S, Yu LS, 2020 VARIDT 1.0: variability of drug transporter database, Yin JY, Sun W, Li FC, Hong JJ, Li XX, Zhou Y, Lu YJ, Liu MZ, Zhang X, Chen N, Jin XP, Xue J, Zeng S, Yu LS, Zhu F, 2020 Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application, Ou F, Zhou Y, Lei JX, Zeng S, Wu FH, Zhang N, Yu LS, 2020 A novel human lncRNA SANT1 cis-regulates the expression of SLC47A2 by altering SFPQ/E2F1/HDAC1 binding to the promoter region in renal cell carcinoma, Gao ZZ, Chen MJ, Tian XK, Chen L, Chen L, Zheng XL, Wang H, Chen JC, Zhao A, Yao QQ, Zhu QY, Jin SN, Hu HH, Zeng S, Yu LS, 2019 Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2, Chen L, Chen L, Qin ZY, Lei JX, Ye S, Zeng K, Wang H, Ying MD, Gao JQ, Zeng S, Yu LS, 2019 Regulation of OCT2 transcriptional repression by histone acetylation in renal cell carcinoma, Zhu QY, Yu LS, Qin ZY, Chen L, Hu HH, Zheng XL, Zeng S, 2019 Studies on the L-2-hydroxy-acid oxidase 2 catalyzed metabolism of S-mandelic acid and its analogues, Zhang Y, Su C, Lei JX, Chen L, Hu HH, Zeng S, Yu LS, 2019 Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state, Ye CN, Han K, Lei JX, Zeng K, Zeng S, Ju HX, Yu LS, 2018 The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants, Yang ZZ, Li L, Wang L, Yuan LM, Xu MC, Gu JK, Jiang HD, Yu LS, Zeng S, 2017 “Ghost peak” of clofazimine: solution degradation product of clofazimine via nucleophilicsubstitution by nitrite leaching from certain glass HPLC vials, Lin J, Lin Z, Li D, Feng M, Yang Q, Hu W, Han Y, Zhu W, Li M, Yu LS, 2017 Brain-derived neurotrophic factor involved epigenetic repression of UGT2B7 in colorectal carcinoma: A mechanism to alter morphine glucuronidation in tumor, Yang ZZ, Li L, Xu MC, Ju HX, Hao M, Gu JK, Jim Wang ZJ, Jiang HD, Yu LS, Zeng S, 2017 Dimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities, Liu YQ, Yuan LM, Gao ZZ, Xiao YS, Sun HY, Yu LS, Zeng S, 2016 siRNA capsulated brain-targeted nanoparticles specifically knock down OATP2B1 in mice: a mechanism for acute morphine tolerance suppression, Yang ZZ, Li L, Wang L, Xu MC, An S, Jiang C, Gu JK, Wang ZJ, Yu LS, Zeng S, 2016 Reverse of acute and chronic morphine tolerance by lithocholic acid via down-regulating UGT2B7, Yang ZZ, Li L, Hu HH, Xu MC, Gu JK, Wang ZJ, Yu LS, Zeng S, 2016 Utilizing single- and double-transfected cell models expressing human organic anion transporter 1 and human cytochrome P450 1A2 to investigate the interactions with ingredients of herbal medicines, Qin Z, Zhao L, Hu H, Jiang H, Yu LS, Zeng S, 2017 Evodia alkaloids suppress gluconeogenesis and lipogenesis by activating the constitutive androstane receptor, Yu LS, Wang ZT, Huang MM, Li YY, Zeng K, Lei JX, Hu HH, Chen BA, Lu J, Xie W, Zeng S, 2016 Platinum(II)-oligonucleotide coordination based aptasensor for simple and selective detection of platinum compounds, Cai S, Tian XK, Sun LL, Hu HH, Zheng SR, Jiang HD, Yu LS, Zeng S, 2015 Regulation of uridine

Areas of Focus

Drug Metabolism and Pharmacokinetics Research
Drug Analysis and New Drug Quality Standards Research
Epigenetic Mechanisms in Drug Metabolism Enzymes and Transporters

Publications

Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin, Liu YQ, Zheng XL, Yu QQ, Wang H, Tan FQ, Zhu QY, Yuan LM, Jiang HD, Yu LS*, Zeng S*, 2016
Downregulation of the farnesoid X receptor promotes colorectal tumorigenesis by facilitating enterotoxigenic Bacteroides fragilis colonization, Guo SH, Peng Y, Lou Y, Cao LJ, Liu JQ, Lin NM, Cai S, Kang Y, Zeng S, Yu LS*, 2022
Oncopeptide MBOP encoded by LINC01234 promotes colorectal cancer through MAPK signaling pathway, Tang CY, Zhou Y, Sun W, Hu HH, Liu YX, Chen L, Ou FT, Zeng S, Lin NM, Yu LS*, 2022
Blockade LAT1 mediates methionine metabolism to overcome oxaliplatin resistance under hypoxia in renal cell carcinoma, Xu QW, Liu YX, Sun W, Song TT, Jiang XT, Zeng K, Zeng S, Chen L*, Yu LS*, 2022
The metabolic stability of antimicrobial peptides IK8 in plasma and liver S9, Mao YY, Zhou SJ, Xu MC, Zeng S, Fan WM, Yu LS*, Lin NM*, 2021
Metastatic colorectal cancer: Perspectives on long non-coding RNAs and promising therapeutics, Tang CY, Liu JQ, Hu QQ, Zeng S, Yu LS*, 2021
Epigenetic regulation of intestinal peptide transporter PEPT1 as a potential strategy for colorectal cancer sensitization, Wang YH, Wang JQ, Yang LR, Qiu LQ, Hua YH, Wu SX, Zeng S, Yu LS*, Zheng XL*, 2021
Regulation of MRP4 Expression by circHIPK3 via Sponging miR-124-3p/miR-4524-5p in Hepatocellular Carcinoma, Hu HH, Wang Y, Qin ZY, Sun W, Chen YH, Wang JQ, Wang YY, Nie J, Chen L, Cai S, Yu LS*, Zeng S*, 2021
INTEDE: interactome of drug-metabolizing enzymes, Yin JY, Li FC, Zhou Y, Mou MJ, Lu YJ, Chen KL, Xue J, Luo YC, Fu JB, He X, Gao JQ, Zeng S*, Yu LS*, Zhu F*, 2021
miR-224-5p Contained in Urinary Extracellular Vesicles Regulates PD-L1 Expression by Inhibiting Cyclin D1 in Renal Cell Carcinoma Cells, Qin ZY, Hu HH, Sun W, Chen L, Jin SN, Xu QW, Liu YX, Yu LS*, Zeng S*, 2021
LncRNA regulation: New frontiers in epigenetic solutions to drug chemoresistance, Zhou Y, Sun W, Qin ZY, Zeng S, Yu LS*, 2020
The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma, Chen L, Wang ZY, Xu QW, Liu YX, Chen L, Guo SH, Wang H, Zeng K, Liu JQ, Zeng S*, Yu LS*, 2020
6-Dithio-2'-deoxyguanosine analogs induce reactive oxygen species-mediated tumor cell apoptosis via bi-targeting thioredoxin 1 and telomerase, Zhang Y, Zhou JB, Ye Q, Zeng K, Pan J, Chen L, Wang YY, Yang B, He QJ, Gao JQ, Zeng S, Yu LS*, 2020
Epigenetic mechanisms underlying OSTβ repression in colorectal cancer, Zhou Y, Ye CN, Lou Y, Liu JQ, Ye S, Chen L, Lei JX, Guo SH, Zeng S, Yu LS*, 2020
The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents, Zhou JB, Kang Y, Chen L, Wang H, Liu JQ, Zeng S, Yu LS*, 2020
Research and development of drug delivery systems based on drug transporter and nano-formulation, Peng Y, Chen L, Ye S, Kang Y, Liu JQ, Zeng S, Yu LS*, 2020
VARIDT 1.0: variability of drug transporter database, Yin JY, Sun W, Li FC, Hong JJ, Li XX, Zhou Y, Lu YJ, Liu MZ, Zhang X, Chen N, Jin XP, Xue J, Zeng S*, Yu LS*, Zhu F*, 2020
Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application, Ou F, Zhou Y, Lei JX, Zeng S, Wu FH, Zhang N*, Yu LS*, 2020
A novel human lncRNA SANT1 cis-regulates the expression of SLC47A2 by altering SFPQ/E2F1/HDAC1 binding to the promoter region in renal cell carcinoma, Gao ZZ, Chen MJ, Tian XK, Chen L, Chen L, Zheng XL, Wang H, Chen JC, Zhao A, Yao QQ, Zhu QY, Jin SN, Hu HH, Zeng S*, Yu LS*, 2019
Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2, Chen L, Chen L, Qin ZY, Lei JX, Ye S, Zeng K, Wang H, Ying MD, Gao JQ, Zeng S, Yu LS*, 2019
Regulation of OCT2 transcriptional repression by histone acetylation in renal cell carcinoma, Zhu QY*, Yu LS*, Qin ZY, Chen L, Hu HH, Zheng XL, Zeng S, 2019
Studies on the L-2-hydroxy-acid oxidase 2 catalyzed metabolism of S-mandelic acid and its analogues, Zhang Y, Su C, Lei JX, Chen L, Hu HH, Zeng S, Yu LS*, 2019
Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state, Ye CN, Han K, Lei JX, Zeng K, Zeng S, Ju HX*, Yu LS*, 2018
The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants, Yang ZZ, Li L, Wang L, Yuan LM, Xu MC, Gu JK, Jiang HD, Yu LS*, Zeng S*, 2017
“Ghost peak” of clofazimine: solution degradation product of clofazimine via nucleophilicsubstitution by nitrite leaching from certain glass HPLC vials, Lin J, Lin Z, Li D, Feng M, Yang Q, Hu W, Han Y, Zhu W, Li M*, Yu LS*, 2017
Brain-derived neurotrophic factor involved epigenetic repression of UGT2B7 in colorectal carcinoma: A mechanism to alter morphine glucuronidation in tumor, Yang ZZ, Li L, Xu MC, Ju HX, Hao M, Gu JK, Jim Wang ZJ, Jiang HD, Yu LS*, Zeng S*, 2017
Dimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities, Liu YQ, Yuan LM, Gao ZZ, Xiao YS, Sun HY, Yu LS*, Zeng S*, 2016
siRNA capsulated brain-targeted nanoparticles specifically knock down OATP2B1 in mice: a mechanism for acute morphine tolerance suppression, Yang ZZ, Li L, Wang L, Xu MC, An S, Jiang C, Gu JK, Wang ZJ, Yu LS*, Zeng S*, 2016
Reverse of acute and chronic morphine tolerance by lithocholic acid via down-regulating UGT2B7, Yang ZZ, Li L, Hu HH, Xu MC, Gu JK, Wang ZJ, Yu LS*, Zeng S*, 2016
Utilizing single- and double-transfected cell models expressing human organic anion transporter 1 and human cytochrome P450 1A2 to investigate the interactions with ingredients of herbal medicines, Qin Z, Zhao L, Hu H, Jiang H, Yu LS*, Zeng S*, 2017
Evodia alkaloids suppress gluconeogenesis and lipogenesis by activating the constitutive androstane receptor, Yu LS, Wang ZT, Huang MM, Li YY, Zeng K, Lei JX, Hu HH, Chen BA, Lu J, Xie W, Zeng S, 2016
Platinum(II)-oligonucleotide coordination based aptasensor for simple and selective detection of platinum compounds, Cai S, Tian XK, Sun LL, Hu HH, Zheng SR, Jiang HD, Yu LS*, Zeng S*, 2015
Regulation of uridine

Drug Metabolism Pharmacokinetics Epigenetics Transporters Enzymes Drug Resistance New Drug Development Quality Standards Clinical Pharmacology Non-Clinical Research

Nengneng Cheng - Fudan University

Weimin Cai - Fudan University

Qingfeng He - Fudan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us